A comprehensive review on the role of mesenchymal stromal/stem cells in the management of rheumatoid arthritis

References

• Smolen JS, Aletaha D, Barton A, et al. Rheumatoid arthritis. Nat Rev Dis Primers. 2018;4(1):18001. doi: 10.1038/nrdp.2018.1
   PubMed Web of Science ®Google Scholar
• Weyand CM, Goronzy JJ. The immunology of rheumatoid arthritis. Nat Immunol. 2021;22(1):10–18.
   PubMed Web of Science ®Google Scholar
• Yang M, Liu Y, Mo B, et al. Helios but not CD226, TIGIT and Foxp3 is a potential marker for CD4+ treg cells in patients with rheumatoid arthritis. Cell Physiol Biochem. 2019;52:1178–1192.
   PubMedGoogle Scholar
• Kanjana K, Chevaisrakul P, Matangkasombut P, et al. Inhibitory activity of FOXP3+ regulatory T cells reveals high specificity for displaying immune tolerance in remission state rheumatoid arthritis. Sci Rep. 2020;10(1):19789. doi: 10.1038/s41598-020-76168-1
   PubMed Web of Science ®Google Scholar
• Go E, Yoo S-J, Choi S, et al. Peripheral blood from rheumatoid arthritis patients shows decreased treg CD25 expression and reduced frequency of effector treg subpopulation. Cells. 2021;10(4):801. doi: 10.3390/cells10040801
   PubMed Web of Science ®Google Scholar
• Nygaard G, Firestein GS. Restoring synovial homeostasis in rheumatoid arthritis by targeting fibroblast-like synoviocytes. Nat Rev Rheumatol. 2020;16(6):316–333. doi: 10.1038/s41584-020-0413-5
   PubMed Web of Science ®Google Scholar
• McInnes IB, Schett G. Cytokines in the pathogenesis of rheumatoid arthritis. Nat Rev Immunol. 2007;7(6):429–442. doi: 10.1038/nri2094
   PubMed Web of Science ®Google Scholar
• McInnes IB, Schett G. The Pathogenesis of Rheumatoid Arthritis. N Engl J Med. 2011;365(23):2205–2219. doi: 10.1056/NEJMra1004965
   PubMed Web of Science ®Google Scholar
• Alten R, Mischkewitz M. 2021 ACR guideline reflects changes in RA treatment. Nat Rev Rheumatol. 2021;17:513–514. doi: 10.1038/s41584-021-00667-2
   PubMed Web of Science ®Google Scholar
• Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res. 2021;73(7):924–939. doi: 10.1002/acr.24596
   PubMed Web of Science ®Google Scholar
• Ansboro S, Roelofs AJ, De Bari C. Mesenchymal stem cells for the management of rheumatoid arthritis: immune modulation, repair or both? Curr Opin Rheumatol. 2017;29(2):201–207. doi: 10.1097/BOR.0000000000000370
   PubMed Web of Science ®Google Scholar
• Nouri B, Nair N, Barton A. Predicting treatment response to IL6R blockers in rheumatoid arthritis. Rheumatology. 2020;59(12):3603–3610. doi: 10.1093/rheumatology/keaa529
   PubMed Web of Science ®Google Scholar
• Her M, Kavanaugh A. Alterations in immune function with biologic therapies for autoimmune disease. J Allergy Clin Immunol. 2016;137(1):19–27. doi: 10.1016/j.jaci.2015.10.023
   PubMed Web of Science ®Google Scholar
• Ozen G, Pedro S, England BR, et al. Risk of serious infection in patients with rheumatoid arthritis treated with biologic versus nonbiologic disease‐modifying antirheumatic drugs. ACR Open Rheumatol. 2019;1(7):424–432. doi: 10.1002/acr2.11064
   PubMedGoogle Scholar
• Markov A, Thangavelu L, Aravindhan S, et al. Mesenchymal stem/stromal cells as a valuable source for the treatment of immune-mediated disorders. Stem Cell Res Ther. 2021;12(1):192. doi: 10.1186/s13287-021-02265-1
   PubMed Web of Science ®Google Scholar
• Dominici M, Le Blanc K, Mueller I, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006;8:315–317. doi: 10.1080/14653240600855905
   PubMed Web of Science ®Google Scholar
• Weiss ARR, Dahlke MH. Immunomodulation by Mesenchymal Stem Cells (MSCs): mechanisms of action of living, apoptotic, and dead MSCs. Front Immunol. 2019;10:1191. doi: 10.3389/fimmu.2019.01191
   PubMed Web of Science ®Google Scholar
• Song N, Scholtemeijer M, Shah K. Mesenchymal stem cell immunomodulation: mechanisms and therapeutic potential. Trends Pharmacol Sci. 2020;41(9):653–664. doi: 10.1016/j.tips.2020.06.009
   PubMed Web of Science ®Google Scholar
• Zhang Q, Li Q, Zhu J, et al. Comparison of therapeutic effects of different mesenchymal stem cells on rheumatoid arthritis in mice. PeerJ. 2019;7:e7023. doi: 10.7717/peerj.7023
   PubMed Web of Science ®Google Scholar
• Luque-Campos N, Contreras-López RA, Jose Paredes-Martínez M, et al. Mesenchymal stem cells improve rheumatoid arthritis progression by controlling memory T cell response. Front Immunol. 2019;10:798. doi: 10.3389/fimmu.2019.00798
   PubMed Web of Science ®Google Scholar
• Li Y, Sheng Q, Zhang C, et al. STAT6 up-regulation amplifies M2 macrophage anti-inflammatory capacity through mesenchymal stem cells. Int Immunopharmacol. 2021;91:107266. doi: 10.1016/j.intimp.2020.107266
   PubMed Web of Science ®Google Scholar
• Yao M, Cui B, Zhang W, et al. Exosomal miR-21 secreted by IL-1β-primed-mesenchymal stem cells induces macrophage M2 polarization and ameliorates sepsis. Life Sci. 2021;264:118658. doi: 10.1016/j.lfs.2020.118658
   PubMed Web of Science ®Google Scholar
• Müller L, Tunger A, Wobus M, et al. Immunomodulatory properties of mesenchymal stromal cells: an update. Front Cell Dev Biol [Internet]. 2021 [cited 2023 Aug 11];9. Available from: https://www.frontiersin.org/articles/10.3389/fcell.2021.637725
   Web of Science ®Google Scholar
• Gao F, Chiu SM, Motan DA, et al. Mesenchymal stem cells and immunomodulation: current status and future prospects. Cell Death Dis. 2016;7:e2062–e2062. doi: 10.1038/cddis.2015.327
   PubMed Web of Science ®Google Scholar
• Almutairi K, Nossent J, Preen D, et al. The global prevalence of rheumatoid arthritis: a meta-analysis based on a systematic review. Rheumatol Int. 2021;41(5):863–877. doi: 10.1007/s00296-020-04731-0
   PubMed Web of Science ®Google Scholar
• Nepom GT, Erlich H. MHC Class-II Molecules and Autoimmunity. Annu Rev Immunol. 1991;9(1):493–525. doi: 10.1146/annurev.iy.09.040191.002425
   PubMedGoogle Scholar
• Gregersen PK, Silver J, Winchester RJ. The shared epitope hypothesis. An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. Arthritis Rheum. 1987;30(11):1205–1213. doi: 10.1002/art.1780301102
   PubMed Web of Science ®Google Scholar
• Karami J, Aslani S, Jamshidi A, et al. Genetic implications in the pathogenesis of rheumatoid arthritis; an updated review. Gene. 2019;702:8–16. doi: 10.1016/j.gene.2019.03.033
   PubMed Web of Science ®Google Scholar
• Wu X, Liu Y, Jin S, et al. Single-cell sequencing of immune cells from anticitrullinated peptide antibody positive and negative rheumatoid arthritis. Nat Commun. 2021;12(1):4977. doi: 10.1038/s41467-021-25246-7
   PubMed Web of Science ®Google Scholar
• Padyukov L. Genetics of rheumatoid arthritis. Semin Immunopathol [Internet]. 2022 [cited 2022 Feb 10];44(1):47–62. doi: 10.1007/s00281-022-00912-0
   PubMed Web of Science ®Google Scholar
• Ha E, Bae S-C, Kim K. Large-scale meta-analysis across East Asian and European populations updated genetic architecture and variant-driven biology of rheumatoid arthritis, identifying 11 novel susceptibility loci. Ann Rheum Dis. 2021;80(5):558–565. doi: 10.1136/annrheumdis-2020-219065
   PubMed Web of Science ®Google Scholar
• Ishigaki K, Sakaue S, Terao C, et al. Trans-ancestry genome-wide association study identifies novel genetic mechanisms in rheumatoid arthritis [Internet]. medRxiv. 2021 [cited 2022 Feb 16]. Available from: https://www.medrxiv.org/content/10.1101/2021.12.01.21267132v1
   Google Scholar
• Travers TS, Harlow L, Rosas IO, et al. Extensive citrullination promotes immunogenicity of HSP90 through protein unfolding and exposure of cryptic epitopes. J Immunol. 2016;197(5):1926–1936. doi: 10.4049/jimmunol.1600162
   PubMed Web of Science ®Google Scholar
• Vossenaar ER, Zendman AJW, van Venrooij WJ, et al. PAD, a growing family of citrullinating enzymes: genes, features and involvement in disease. BioEssays. 2003;25(11):1106–1118. doi: 10.1002/bies.10357
   PubMed Web of Science ®Google Scholar
• Curran AM, Naik P, Giles JT, et al. PAD enzymes in rheumatoid arthritis: pathogenic effectors and autoimmune targets. Nat Rev Rheumatol. 2020;16(6):301–315. doi: 10.1038/s41584-020-0409-1
   PubMed Web of Science ®Google Scholar
• Makrygiannakis D, Af KE, Lundberg IE, et al. Citrullination is an inflammation-dependent process. Ann Rheumatic Dis. 2006;65(9):1219–1222. doi: 10.1136/ard.2005.049403
   PubMed Web of Science ®Google Scholar
• Sipilä KH, Ranga V, Rappu P, et al. Joint inflammation related citrullination of functional arginines in extracellular proteins. Sci Rep. 2017;7(1):8246. doi: 10.1038/s41598-017-08597-4
   PubMedGoogle Scholar
• Laugisch O, Wong A, Sroka A, et al. Citrullination in the periodontium—a possible link between periodontitis and rheumatoid arthritis. Clin Oral Invest. 2016;20(4):675–683. doi: 10.1007/s00784-015-1556-7
   PubMed Web of Science ®Google Scholar
• González-Febles J, Sanz M. Periodontitis and rheumatoid arthritis: What have we learned about their connection and their treatment? Periodontol 2000. 2021;87:181–203. doi: 10.1111/prd.12385
   PubMed Web of Science ®Google Scholar
• Ishikawa Y, Terao C. The impact of cigarette smoking on risk of rheumatoid arthritis: a narrative review. Cells. 2020;9(2):475. doi: 10.3390/cells9020475
   PubMed Web of Science ®Google Scholar
• Kay J, Upchurch KS. ACR/EULAR 2010 rheumatoid arthritis classification criteria. Rheumatology. 2012;51(suppl 6):vi5–vi9. doi: 10.1093/rheumatology/kes279
   PubMed Web of Science ®Google Scholar
• de Brito Rocha S, Baldo DC, Andrade LEC. Clinical and pathophysiologic relevance of autoantibodies in rheumatoid arthritis. Adv Rheumatology. 2019;59(1):2. doi: 10.1186/s42358-018-0042-8
   Google Scholar
• Sokolova MV, Schett G, Steffen U. Autoantibodies in rheumatoid arthritis: historical background and novel findings. Clinic Rev Allerg Immunol. 2021 [cited 2022 Apr 5];63(2):138–151. doi: 10.1007/s12016-021-08890-1
   PubMed Web of Science ®Google Scholar
• Shi J, Knevel R, Suwannalai P, et al. Autoantibodies recognizing carbamylated proteins are present in sera of patients with rheumatoid arthritis and predict joint damage. Proceedings of the National Academy of Sciences. 2011;108. p. 17372–17377. doi: 10.1073/pnas.1114465108
   Google Scholar
• Humphreys J, Verheul M, Barton A, et al. Association of anti-carbamylated protein antibodies with long-term disability and increased disease activity in patients with early inflammatory arthritis: results from the Norfolk Arthritis Register. Lancet. 2015;385:S44. doi: 10.1016/S0140-6736(15)60359-2
   PubMed Web of Science ®Google Scholar
• Regueiro C, Nuño L, Ortiz AM, et al. Value of Measuring Anti-carbamylated protein antibodies for classification on early arthritis patients. Sci Rep. 2017;7(1):12023. doi: 10.1038/s41598-017-09657-5
   PubMedGoogle Scholar
• Ceccarelli F, Perricone C, Colasanti T, et al. Anti-carbamylated protein antibodies as a new biomarker of erosive joint damage in systemic lupus erythematosus. Arthritis Res Ther. 2018;20(1):126. doi: 10.1186/s13075-018-1622-z
   PubMedGoogle Scholar
• Elsawy NA, Mohamed RA, Ghazala RA, et al. Anti-carbamylated protein antibodies in premenopausal rheumatoid arthritis women: relation to disease activity and bone loss. Rheumatology. 2021;60(3):1419–1428. doi: 10.1093/rheumatology/keaa549
   PubMed Web of Science ®Google Scholar
• Zhang B, Lei Y, Li X, et al. Elevated levels of anti-carbamylated protein antibody in patients with rheumatoid arthritis: association with disease activity and bone destruction. J Invest Med. 2020;68(6):1186–1192. doi: 10.1136/jim-2019-001249
   PubMed Web of Science ®Google Scholar
• Hussein MS, Gaber RA, Elsabagh HM, et al. Do anti-carbamylated protein antibodies in rheumatoid arthritis reflect local and systemic osteoporosis? A study of osteoprotegrin and receptor activator for nuclear factor kappa B ligand and radiological assessment. Egypt Rheumatol Rehabil. 2021;48(1):18. doi: 10.1186/s43166-021-00067-0
   Google Scholar
• Castellanos-Moreira R, Rodríguez-García SC, Gomara MJ, et al. Anti-carbamylated proteins antibody repertoire in rheumatoid arthritis: evidence of a new autoantibody linked to interstitial lung disease. Ann Rheumatic Dis. 2020;79(5):587–594. doi: 10.1136/annrheumdis-2019-216709
   PubMed Web of Science ®Google Scholar
• Oka S, Higuchi T, Furukawa H, et al. Serum rheumatoid factor IgA, anti-citrullinated peptide antibodies with secretory components, and anti-carbamylated protein antibodies associate with interstitial lung disease in rheumatoid arthritis. BMC Musculoskelet Disord. 2022;23(1):46. doi: 10.1186/s12891-021-04985-0
   PubMed Web of Science ®Google Scholar
• Riccardi A, Martinroche G, Contin-Bordes C, et al. Erosive arthritis autoantibodies in systemic sclerosis. Semin Arthritis Rheum. 2022;52:151947. doi: 10.1016/j.semarthrit.2021.11.013
   PubMed Web of Science ®Google Scholar
• Alpizar-Rodriguez D, Finckh A. Is the prevention of rheumatoid arthritis possible? Clin Rheumatol. 2020;39(5):1383–1389. doi: 10.1007/s10067-020-04927-6
   PubMed Web of Science ®Google Scholar
• Finckh A, Escher M, Liang MH, et al. Preventive treatments for rheumatoid arthritis: issues regarding patient preferences. Curr Rheumatol Rep. 2016;18(8):51. doi: 10.1007/s11926-016-0598-4
   PubMed Web of Science ®Google Scholar
• O’Neil LJ, Deane KD. Striking a balance in rheumatoid arthritis prevention trials. Nat Rev Rheumatol. 2021;17(7):385–386. doi: 10.1038/s41584-021-00627-w
   PubMed Web of Science ®Google Scholar
• Mosor E, Stoffer-Marx M, Steiner G, et al. I would never take preventive medication! Perspectives and information needs of people who underwent predictive tests for rheumatoid arthritis. Arthritis Care Res. 2020;72(3):360–368. doi: 10.1002/acr.23841
   Web of Science ®Google Scholar
• Lahiri M, Morgan C, Symmons DPM, et al. Modifiable risk factors for RA: prevention, better than cure? Rheumatology (Oxford). 2012;51(3):499–512. doi: 10.1093/rheumatology/ker299
   PubMed Web of Science ®Google Scholar
• Salliot C, Nguyen Y, Boutron-Ruault M-C, et al. Environment and lifestyle: their influence on the risk of RA. J Clin Med. 2020;9(10):E3109. doi: 10.3390/jcm9103109
   PubMed Web of Science ®Google Scholar
• Ye D, Mao Y, Xu Y, et al. Lifestyle factors associated with incidence of rheumatoid arthritis in US adults: analysis of National Health and Nutrition Examination Survey database and meta-analysis. BMJ Open. 2021;11(1):e038137. doi: 10.1136/bmjopen-2020-038137
   PubMed Web of Science ®Google Scholar
• Kronzer VL, Huang W, Dellaripa PF, et al. Lifestyle and clinical risk factors for incident rheumatoid arthritis-associated interstitial lung disease. J Rheumatol. 2021;48(5):656–663. doi: 10.3899/jrheum.200863
   PubMed Web of Science ®Google Scholar
• Zaccardelli A, Friedlander HM, Ford JA, et al. Potential of lifestyle changes for reducing the risk of developing rheumatoid arthritis: is an ounce of prevention worth a pound of cure? Clin Ther. 2019;41(7):1323–1345. doi: 10.1016/j.clinthera.2019.04.021
   PubMed Web of Science ®Google Scholar
• Ro J, Kim SH, Kim H-R, et al. Impact of lifestyle and comorbidities on seropositive rheumatoid arthritis risk from Korean health insurance data. Sci Rep. 2022;12(1):2201. doi: 10.1038/s41598-022-06194-8
   PubMed Web of Science ®Google Scholar
• Gwinnutt JM, Verstappen SM, Humphreys JH. The impact of lifestyle behaviours, physical activity and smoking on morbidity and mortality in patients with rheumatoid arthritis. Best Pract Res Clin Rheumatol. 2020;34(2):101562. doi: 10.1016/j.berh.2020.101562
   PubMed Web of Science ®Google Scholar
• Hollan I, Dessein PH, Ronda N, et al. Prevention of cardiovascular disease in rheumatoid arthritis. Autoimmun Rev. 2015;14(10):952–969. doi: 10.1016/j.autrev.2015.06.004
   PubMed Web of Science ®Google Scholar
• van Boheemen L, Bolt JW, Ter Wee MM, et al. Patients’ and rheumatologists’ perceptions on preventive intervention in rheumatoid arthritis and axial spondyloarthritis. Arthritis Res Ther. 2020;22(1):217. doi: 10.1186/s13075-020-02314-9
   PubMed Web of Science ®Google Scholar
• Gwinnutt JM, Wieczorek M, Balanescu A, et al. 2021 EULAR recommendations regarding lifestyle behaviours and work participation to prevent progression of rheumatic and musculoskeletal diseases. Ann Rheum Dis [Internet]. 2022 Apr 11. Available from: https://ard.bmj.com/content/early/2022/03/07/annrheumdis-2021-222020
   Web of Science ®Google Scholar
• Wieczorek M, Gwinnutt JM, Ransay-Colle M, et al. Smoking, alcohol consumption and disease-specific outcomes in rheumatic and musculoskeletal diseases (RMDs): systematic reviews informing the 2021 EULAR recommendations for lifestyle improvements in people with RMDs. RMD Open. 2022;8(1):e002170. doi: 10.1136/rmdopen-2021-002170
   PubMed Web of Science ®Google Scholar
• Combe B. Progression in early rheumatoid arthritis. Best Pract Res Clin Rheumatol. 2009;23(1):59–69. doi: 10.1016/j.berh.2008.11.006
   PubMedGoogle Scholar
• Figus FA, Piga M, Azzolin I, et al. Rheumatoid arthritis: Extra-articular manifestations and comorbidities. Autoimmun Rev. 2021;20(4):102776. doi: 10.1016/j.autrev.2021.102776
   PubMed Web of Science ®Google Scholar
• Rezuș E, Macovei LA, Burlui AM, et al. Ischemic heart disease and rheumatoid arthritis—two conditions, the same background. Life (Basel). 2021;11(10):1042. doi: 10.3390/life11101042
   PubMed Web of Science ®Google Scholar
• DeMizio DJ, Geraldino-Pardilla LB. Autoimmunity and inflammation link to cardiovascular disease risk in rheumatoid arthritis. Rheumatol Ther. 2020;7(1):19–33. doi: 10.1007/s40744-019-00189-0
   PubMed Web of Science ®Google Scholar
• Ahmed S, Jacob B, Carsons SE, et al. Treatment of cardiovascular disease in rheumatoid arthritis: a complex challenge with increased atherosclerotic risk. Pharmaceuticals (Basel). 2021;15(1):11. doi: 10.3390/ph15010011
   PubMedGoogle Scholar
• Agca R, Heslinga SC, Rollefstad S, et al. EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update. Ann Rheumatic Dis. 2017;76(1):17–28. doi: 10.1136/annrheumdis-2016-209775
   PubMed Web of Science ®Google Scholar
• Sparks JA, Jin Y, Cho S-K, et al. Prevalence, incidence and cause-specific mortality of rheumatoid arthritis–associated interstitial lung disease among older rheumatoid arthritis patients. Rheumatology (Oxford). 2021;60(8):3689–3698. doi: 10.1093/rheumatology/keaa836
   PubMed Web of Science ®Google Scholar
• Akiyama M, Kaneko Y. Pathogenesis, clinical features, and treatment strategy for rheumatoid arthritis-associated interstitial lung disease. Autoimmun Rev. 2022;21(5):103056. doi: 10.1016/j.autrev.2022.103056
   PubMed Web of Science ®Google Scholar
• Luppi F, Sebastiani M, Salvarani C, et al. Acute exacerbation of interstitial lung disease associated with rheumatic disease. Nat Rev Rheumatol. 2022;18(2):85–96. doi: 10.1038/s41584-021-00721-z
   PubMed Web of Science ®Google Scholar
• Manfredi A, Cassone G, Luppi F, et al. Rheumatoid arthritis related interstitial lung disease. Expert Rev Clin Immunol. 2021;17(5):485–497. doi: 10.1080/1744666X.2021.1905524
   PubMed Web of Science ®Google Scholar
• Demoruelle MK, Deane KD. Treatment strategies in early rheumatoid arthritis and prevention of rheumatoid arthritis. Curr Rheumatol Rep. 2012;14(5):472–480. doi: 10.1007/s11926-012-0275-1
   PubMed Web of Science ®Google Scholar
• Monti S, Montecucco C, Bugatti S, et al. Rheumatoid arthritis treatment: the earlier the better to prevent joint damage. RMD Open. 2015;1(Suppl 1):e000057. doi: 10.1136/rmdopen-2015-000057
   PubMedGoogle Scholar
• Raza K, Filer A. The therapeutic window of opportunity in rheumatoid arthritis: does it ever close? Ann Rheumatic Dis. 2015;74(5):793–794. doi: 10.1136/annrheumdis-2014-206993
   PubMed Web of Science ®Google Scholar
• Hua C, Buttgereit F, Combe B. Glucocorticoids in rheumatoid arthritis: current status and future studies. RMD Open. 2020;6(1):e000536. doi: 10.1136/rmdopen-2017-000536
   PubMed Web of Science ®Google Scholar
• Pelechas E, Drosos AA. State-of-the-art glucocorticoid-targeted drug therapies for the treatment of rheumatoid arthritis. Expert Opin Pharmacother. 2022;23(6):703–711. doi: 10.1080/14656566.2022.2049238
   PubMed Web of Science ®Google Scholar
• Guo Q, Wang Y, Xu D, et al. Rheumatoid arthritis: pathological mechanisms and modern pharmacologic therapies. Bone Res. 2018;6:1–14.
   PubMed Web of Science ®Google Scholar
• Smolen JS, Landewé RBM, Bijlsma JWJ, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheumatic Dis. 2020;79(6):685–699. doi: 10.1136/annrheumdis-2019-216655
   PubMed Web of Science ®Google Scholar
• Wijbrandts CA, Tak PP Prediction of response to targeted treatment in rheumatoid arthritis. Mayo Clinic Proceedings. 2017;92. p. 1129–1143. doi: 10.1016/j.mayocp.2017.05.009
   Google Scholar
• Sarsenova M, Issabekova A, Abisheva S, et al. Mesenchymal stem cell-based therapy for rheumatoid arthritis. Int J Mol Sci. 2021;22(21):11592. doi: 10.3390/ijms222111592
   PubMed Web of Science ®Google Scholar
• Debreova M, Culenova M, Smolinska V, et al. Rheumatoid arthritis: From synovium biology to cell-based therapy. Cytotherapy. 2022;24(4):365–375. doi: 10.1016/j.jcyt.2021.10.003
   PubMed Web of Science ®Google Scholar
• Jasim SA, Yumashev AV, Abdelbasset WK, et al. Shining the light on clinical application of mesenchymal stem cell therapy in autoimmune diseases. Stem Cell Res Ther. 2022;13(1):101. doi: 10.1186/s13287-022-02782-7
   PubMed Web of Science ®Google Scholar
• Lu Y, Li Z, Li L, et al. Highly effective rheumatoid arthritis therapy by peptide-promoted nanomodification of mesenchymal stem cells. Biomaterials. 2022;283:121474. doi: 10.1016/j.biomaterials.2022.121474
   PubMed Web of Science ®Google Scholar
• McCulloch EA, Till JE. Perspectives on the properties of stem cells. Nat Med. 2005;11(10):1026–1028. doi: 10.1038/nm1005-1026
   PubMed Web of Science ®Google Scholar
• Evans MJ, Kaufman MH. Establishment in culture of pluripotential cells from mouse embryos. Nature. 1981;292(5819):154–156. doi: 10.1038/292154a0
   PubMed Web of Science ®Google Scholar
• Martin GR. Isolation of a pluripotent cell line from early mouse embryos cultured in medium conditioned by teratocarcinoma stem cells. Proc Natl Acad Sci USA. 1981;78(12):7634–7638. doi: 10.1073/pnas.78.12.7634
   PubMed Web of Science ®Google Scholar
• Doetschman TC, Eistetter H, Katz M, et al. The in vitro development of blastocyst-derived embryonic stem cell lines: formation of visceral yolk sac, blood islands and myocardium. J Embryol Exp Morphol. 1985;87(1):27–45. doi: 10.1242/dev.87.1.27
   PubMedGoogle Scholar
• Rippon HJ, Bishop AE. Embryonic stem cells. Cell Proliferation. 2004;37(1):23–34. doi: 10.1111/j.1365-2184.2004.00298.x
   PubMed Web of Science ®Google Scholar
• Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006;126(4):663–676. doi: 10.1016/j.cell.2006.07.024
   PubMed Web of Science ®Google Scholar
• Meissner A, Wernig M, Jaenisch R. Direct reprogramming of genetically unmodified fibroblasts into pluripotent stem cells. Nat Biotechnol. 2007;25(10):1177–1181. doi: 10.1038/nbt1335
   PubMed Web of Science ®Google Scholar
• Takahashi K, Tanabe K, Ohnuki M, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 2007;131(5):861–872. doi: 10.1016/j.cell.2007.11.019
   PubMed Web of Science ®Google Scholar
• Yu J, Vodyanik MA, Smuga-Otto K, et al. Induced pluripotent stem cell lines derived from human somatic cells. Science. 2007;318(5858):1917–1920. doi: 10.1126/science.1151526
   PubMed Web of Science ®Google Scholar
• Okita K, Yamanaka S. Induced pluripotent stem cells: opportunities and challenges. Philos Trans R Soc Lond B Biol Sci. 2011;366:2198–2207. doi: 10.1098/rstb.2011.0016
   PubMed Web of Science ®Google Scholar
• Okita K, Nakagawa M, Hyenjong H, et al. Generation of mouse induced pluripotent stem cells without viral vectors. Science. 2008;322(5903):949–953. doi: 10.1126/science.1164270
   PubMed Web of Science ®Google Scholar
• Zhou H, Wu S, Joo JY, et al. Generation of induced pluripotent stem cells using recombinant proteins. Cell Stem Cell. 2009;4(5):381–384. doi: 10.1016/j.stem.2009.04.005
   PubMed Web of Science ®Google Scholar
• Warren L, Manos PD, Ahfeldt T, et al. Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA. Cell Stem Cell. 2010;7(5):618–630. doi: 10.1016/j.stem.2010.08.012
   PubMed Web of Science ®Google Scholar
• Allison TF, Andrews PW, Avior Y, et al. Assessment of established techniques to determine developmental and malignant potential of human pluripotent stem cells. Nat Commun. 2018;9(1):1925. doi: 10.1038/s41467-018-04011-3
   PubMedGoogle Scholar
• Donovan PJ, Gearhart J. The end of the beginning for pluripotent stem cells. Nature. 2001;414(6859):92–97. doi: 10.1038/35102154
   PubMed Web of Science ®Google Scholar
• Till JE, McCulloch EA. A direct measurement of the radiation sensitivity of normal mouse bone marrow cells. Radiat Res. 1961;14:213–222. doi: 10.2307/3570892
   PubMed Web of Science ®Google Scholar
• Becker AJ, McCulloch EA, Till JE. Cytological demonstration of the clonal nature of spleen colonies derived from transplanted mouse marrow cells. Nature. 1963;197:452–454. doi: 10.1038/197452a0
   PubMed Web of Science ®Google Scholar
• Bujko K, Kucia M, Ratajczak J, et al. Hematopoietic stem and progenitor cells (HSPCs). Adv Exp Med Biol. 2019;1201:49–77.
   PubMed Web of Science ®Google Scholar
• Sonoda Y. Immunophenotype and functional characteristics of human primitive CD34-negative hematopoietic stem cells: the significance of the intra-bone marrow injection. J Autoimmun. 2008;30(3):136–144. doi: 10.1016/j.jaut.2007.12.004
   PubMed Web of Science ®Google Scholar
• Mann Z, Sengar M, Verma YK, et al. Hematopoietic stem cell factors: their functional role in self-renewal and clinical aspects. Front Cell Dev Biol [Internet]. 2022 [cited 2023 Mar 17];10. Available from: https://www.frontiersin.org/articles/10.3389/fcell.2022.664261
   Web of Science ®Google Scholar
• Thomas ED, Lochte HL, Lu WC, et al. Intravenous infusion of bone marrow in patients receiving radiation and chemotherapy. N Engl J Med. 1957;257(11):491–496. doi: 10.1056/NEJM195709122571102
   PubMed Web of Science ®Google Scholar
• Gluckman E, Broxmeyer HE, Auerbach AD, et al. Hematopoietic reconstitution in a patient with Fanconi’s anemia by means of umbilical-cord blood from an HLA-Identical sibling. N Engl J Med. 1989;321(17):1174–1178. doi: 10.1056/NEJM198910263211707
   PubMed Web of Science ®Google Scholar
• Hatzimichael E, Tuthill M. Hematopoietic stem cell transplantation. Stem Cells Cloning. 2010;3:105–117. doi: 10.2147/SCCAA.S6815
   PubMedGoogle Scholar
• Greinix HT, Eikema D-J, Koster L, et al. Incidence of acute Graft-Versus-Host disease and survival after allogeneic hematopoietic cell transplantation over time: a study from the transplant complications and chronic malignancies working party of the EBMT. Blood. 2018;132(Supplement 1):2120. doi: 10.1182/blood-2018-99-111764
   Google Scholar
• Bianco P, Cao X, Frenette PS, et al. The meaning, the sense and the significance: translating the science of mesenchymal stem cells into medicine. Nat Med. 2013;19(1):35–42. doi: 10.1038/nm.3028
   PubMed Web of Science ®Google Scholar
• Friedenstein AJ, Deriglasova UF, Kulagina NN, et al. Precursors for fibroblasts in different populations of hematopoietic cells as detected by the in vitro colony assay method. Exp Hematol. 1974;2:83–92.
   PubMed Web of Science ®Google Scholar
• Macrin D, Joseph JP, Pillai AA, et al. Eminent sources of adult mesenchymal stem cells and their therapeutic Imminence. Stem Cell Rev And Rep. 2017;13(6):741–756. doi: 10.1007/s12015-017-9759-8
   PubMed Web of Science ®Google Scholar
• Lv F-J, Tuan RS, Cheung KMC, et al. Concise review: the surface markers and identity of human mesenchymal stem cells. Stem Cells. 2014;32(6):1408–1419. doi: 10.1002/stem.1681
   PubMed Web of Science ®Google Scholar
• Tobiasch E. Differentiation potential of adult human mesenchymal stem cells. In: Artmann G, Minger S Hescheler J editors. Stem cell engineering: principles and applications [Internet]. Berlin (Heidelberg): Springer; 2011 [cited 2023 Mar 20]. p. 61–77. doi: 10.1007/978-3-642-11865-4_3
   Google Scholar
• Suman S, Domingues A, Ratajczak J, et al. Potential clinical applications of stem cells in regenerative medicine. Adv Exp Med Biol. 2019;1201:1–22.
   PubMed Web of Science ®Google Scholar
• da Silva Meirelles L, Caplan AI, Nardi NB. In search of the in vivo identity of mesenchymal stem cells. Stem Cells. 2008;26(9):2287–2299. doi: 10.1634/stemcells.2007-1122
   PubMed Web of Science ®Google Scholar
• Dore-Duffy P, Katychev A, Wang X, et al. CNS microvascular pericytes exhibit multipotential stem Cell activity. J Cereb Blood Flow Metab. 2006;26(5):613–624. doi: 10.1038/sj.jcbfm.9600272
   PubMed Web of Science ®Google Scholar
• Covas DT, Panepucci RA, Fontes AM, et al. Multipotent mesenchymal stromal cells obtained from diverse human tissues share functional properties and gene-expression profile with CD146+ perivascular cells and fibroblasts. Exp Hematol. 2008;36(5):642–654. doi: 10.1016/j.exphem.2007.12.015
   PubMed Web of Science ®Google Scholar
• Janebodin K, Zeng Y, Buranaphatthana W, et al. VEGFR2-dependent angiogenic capacity of pericyte-like dental pulp stem cells. J Dent Res. 2013;92(6):524–531. doi: 10.1177/0022034513485599
   PubMed Web of Science ®Google Scholar
• Pisciotta A, Bertoni L, Vallarola A, et al. Neural crest derived stem cells from dental pulp and tooth-associated stem cells for peripheral nerve regeneration. Neural Regen Res. 2019;15(3):373–381. doi: 10.4103/1673-5374.266043
   Web of Science ®Google Scholar
• Fan X-L, Zhang Y, Li X, et al. Mechanisms underlying the protective effects of mesenchymal stem cell-based therapy. Cell Mol Life Sci. 2020;77(14):2771–2794. doi: 10.1007/s00018-020-03454-6
   PubMed Web of Science ®Google Scholar
• Ferreira JR, Teixeira GQ, Santos SG, et al. Mesenchymal stromal cell secretome: influencing therapeutic potential by cellular pre-conditioning. Front Immunol [Internet]. 2018 [cited 2023 Mar 26];9. doi: 10.3389/fimmu.2018.02837
   Web of Science ®Google Scholar
• Tan L, Liu X, Dou H, et al. Characteristics and regulation of mesenchymal stem cell plasticity by the microenvironment — specific factors involved in the regulation of MSC plasticity. Genes Dis. 2022;9(2):296–309. doi: 10.1016/j.gendis.2020.10.006
   PubMed Web of Science ®Google Scholar
• Shi Y, Hu G, Su J, et al. Mesenchymal stem cells: a new strategy for immunosuppression and tissue repair. Cell Res. 2010;20(5):510–518. doi: 10.1038/cr.2010.44
   PubMed Web of Science ®Google Scholar
• Bulati M, Miceli V, Gallo A, et al. The immunomodulatory properties of the human amnion-derived mesenchymal stromal/stem cells are induced by INF-γ produced by activated lymphomonocytes and are mediated by cell-to-cell contact and soluble factors. Front Immunol [Internet]. 2020 [cited 2023 Mar 26];11. doi: 10.3389/fimmu.2020.00054
   PubMed Web of Science ®Google Scholar
• Noronha NDC, Mizukami A, Caliári-Oliveira C, et al. Priming approaches to improve the efficacy of mesenchymal stromal cell-based therapies. Stem Cell Res Ther. 2019;10(1):131. doi: 10.1186/s13287-019-1224-y
   PubMed Web of Science ®Google Scholar
• Park B-W, Jung S-H, Das S, et al. In vivo priming of human mesenchymal stem cells with hepatocyte growth factor–engineered mesenchymal stem cells promotes therapeutic potential for cardiac repair. Sci Adv. 2020;6(13):eaay6994. doi: 10.1126/sciadv.aay6994
   PubMed Web of Science ®Google Scholar
• Raza SS, Seth P, Khan MA. ‘Primed’ mesenchymal stem cells: a potential novel therapeutic for COVID-19 patients. Stem Cell Rev And Rep. 2021;17(1):153–162. doi: 10.1007/s12015-020-09999-0
   PubMed Web of Science ®Google Scholar
• Naji A, Eitoku M, Favier B, et al. Biological functions of mesenchymal stem cells and clinical implications. Cell Mol Life Sci. 2019;76(17):3323–3348. doi: 10.1007/s00018-019-03125-1
   PubMed Web of Science ®Google Scholar
• Karp JM, Leng Teo GS. Mesenchymal stem cell homing: the devil is in the details. Cell Stem Cell. 2009;4(3):206–216. doi: 10.1016/j.stem.2009.02.001
   PubMed Web of Science ®Google Scholar
• Ullah M, Liu DD, Thakor AS. Mesenchymal stromal cell homing: mechanisms and strategies for improvement. iScience. 2019;15:421–438. doi: 10.1016/j.isci.2019.05.004
   PubMed Web of Science ®Google Scholar
• Yuan M, Hu X, Yao L, et al. Mesenchymal stem cell homing to improve therapeutic efficacy in liver disease. Stem Cell Res Ther. 2022;13(1):179. doi: 10.1186/s13287-022-02858-4
   PubMed Web of Science ®Google Scholar
• Eseonu OI, De Bari C. Homing of mesenchymal stem cells: mechanistic or stochastic? Implications for targeted delivery in arthritis. Rheumatology. 2015;54(2):210–218. doi: 10.1093/rheumatology/keu377
   PubMed Web of Science ®Google Scholar
• Al-Kharboosh R, ReFaey K, Lara-Velazquez M, et al. Inflammatory mediators in glioma microenvironment play a dual role in gliomagenesis and mesenchymal stem cell homing: implication for cellular therapy. Mayo Clinic Proceedings: Innovations, Quality & Outcomes. 2020;4. p. 443–459. doi: 10.1016/j.mayocpiqo.2020.04.006
   Google Scholar
• Gnecchi M, Danieli P, Malpasso G, et al. Paracrine mechanisms of mesenchymal stem cells in tissue repair. In: Gnecchi M, editor. Mesenchymal stem cells: methods and protocols [Internet]. NY (NY): Springer; 2016. [cited 2023 Mar 26]. p. 123–146. doi: 10.1007/978-1-4939-3584-0_7
   Google Scholar
• PK L, Kandoi S, Misra R, et al. The mesenchymal stem cell secretome: A new paradigm towards cell-free therapeutic mode in regenerative medicine. Cytokine Growth Factor Rev. 2019;46:1–9. doi: 10.1016/j.cytogfr.2019.04.002
   PubMed Web of Science ®Google Scholar
• Kim H-S, Choi D-Y, Yun SJ, et al. Proteomic analysis of microvesicles derived from human mesenchymal stem cells. J Proteome Res. 2012;11(2):839–849. doi: 10.1021/pr200682z
   PubMed Web of Science ®Google Scholar
• Dabrowska S, Andrzejewska A, Janowski M, et al. Immunomodulatory and regenerative effects of mesenchymal stem cells and extracellular vesicles: therapeutic outlook for inflammatory and degenerative diseases. Front Immunol. 2020;11:591065. doi: 10.3389/fimmu.2020.591065
   PubMed Web of Science ®Google Scholar
• Lai RC, Arslan F, Lee MM, et al. Exosome secreted by MSC reduces myocardial ischemia/reperfusion injury. Stem Cell Res. 2010;4(3):214–222. doi: 10.1016/j.scr.2009.12.003
   PubMed Web of Science ®Google Scholar
• Kalimuthu S, Gangadaran P, Li XJ, et al. In vivo therapeutic potential of mesenchymal stem cell-derived extracellular vesicles with optical imaging reporter in tumor mice model. Sci Rep. 2016;6(1):30418. doi: 10.1038/srep30418
   PubMedGoogle Scholar
• Ophelders DRMG, Wolfs TGAM, Jellema RK, et al. Mesenchymal stromal cell-derived extracellular vesicles protect the fetal brain after hypoxia-ischemia. Stem Cells Transl Med. 2016;5(6):754–763. doi: 10.5966/sctm.2015-0197
   PubMed Web of Science ®Google Scholar
• Damania A, Jaiman D, Teotia AK, et al. Mesenchymal stromal cell-derived exosome-rich fractionated secretome confers a hepatoprotective effect in liver injury. Stem Cell Res Ther. 2018;9(1):31. doi: 10.1186/s13287-017-0752-6
   PubMedGoogle Scholar
• Ruppert KA, Nguyen TT, Prabhakara KS, et al. Human mesenchymal stromal cell-derived extracellular vesicles modify microglial response and improve clinical outcomes in experimental spinal cord injury. Sci Rep. 2018;8(1):480. doi: 10.1038/s41598-017-18867-w
   PubMedGoogle Scholar
• Driscoll J, Patel T. The mesenchymal stem cell secretome as an acellular regenerative therapy for liver disease. J Gastroenterol. 2019;54(9):763–773. doi: 10.1007/s00535-019-01599-1
   PubMed Web of Science ®Google Scholar
• Sun DZ, Abelson B, Babbar P, et al. Harnessing the mesenchymal stem cell secretome for regenerative urology. Nat Rev Urol. 2019;16(6):363–375. doi: 10.1038/s41585-019-0169-3
   PubMed Web of Science ®Google Scholar
• Ahangar P, Mills SJ, Cowin AJ. Mesenchymal stem cell secretome as an emerging Cell-free alternative for improving wound repair. Int J Mol Sci. 2020;21(19):7038. doi: 10.3390/ijms21197038
   PubMed Web of Science ®Google Scholar
• Rosochowicz MA, Lach MS, Richter M, et al. Conditioned medium – is it an undervalued lab waste with the potential for osteoarthritis management? Stem Cell Rev And Rep [Internet]. 2023 [[cited 2023 Mar 26]];19(5):1185–1213. doi: 10.1007/s12015-023-10517-1
   PubMed Web of Science ®Google Scholar
• Ikehara S, Good RA, Nakamura T, et al. Rationale for bone marrow transplantation in the treatment of autoimmune diseases. Proc Natl Acad Sci U S A. 1985;82(8):2483–2487. doi: 10.1073/pnas.82.8.2483
   PubMed Web of Science ®Google Scholar
• van Bekkum DW, Bohre EP, Houben PF, et al. Regression of adjuvant-induced arthritis in rats following bone marrow transplantation. Proc Natl Acad Sci, USA. 1989;86(24):10090–10094. doi: 10.1073/pnas.86.24.10090
   PubMed Web of Science ®Google Scholar
• Smith-Berdan S, Gille D, Weissman IL, et al. Reversal of autoimmune disease in lupus-prone New Zealand black/New Zealand white mice by nonmyeloablative transplantation of purified allogeneic hematopoietic stem cells. Blood. 2007;110(4):1370–1378. doi: 10.1182/blood-2007-03-081497
   PubMed Web of Science ®Google Scholar
• Sullivan KM, Shah A, Sarantopoulos S, et al. Review: hematopoietic stem cell transplantation for scleroderma: effective immunomodulatory therapy for patients with pulmonary involvement. Arthritis & Rheumat. 2016;68(10):2361–2371. doi: 10.1002/art.39748
   PubMed Web of Science ®Google Scholar
• Snowden JA, Passweg J, Moore JJ, et al. Autologous hemopoietic stem cell transplantation in severe rheumatoid arthritis: a report from the EBMT and ABMTR. J Rheumatol. 2004;31(3):482–488.
   PubMed Web of Science ®Google Scholar
• Gratwohl A, Passweg J, Bocelli-Tyndall C, et al. Autologous hematopoietic stem cell transplantation for autoimmune diseases. Bone Marrow Transplant. 2005;35(9):869–879. doi: 10.1038/sj.bmt.1704892
   PubMed Web of Science ®Google Scholar
• Farge D, Labopin M, Tyndall A, et al. Autologous hematopoietic stem cell transplantation for autoimmune diseases: an observational study on 12 years’ experience from the European group for blood and marrow transplantation working party on autoimmune diseases. Haematologica. 2010;95:284–292. doi: 10.3324/haematol.2009.013458
   PubMed Web of Science ®Google Scholar
• Franceschetti T, De Bari C. The potential role of adult stem cells in the management of the rheumatic diseases. Ther Adv Musculoskelet Dis. 2017;9(7):165–179. doi: 10.1177/1759720X17704639
   PubMed Web of Science ®Google Scholar
• Colmegna I, Weyand CM. Haematopoietic stem and progenitor cells in rheumatoid arthritis. Rheumatology (Oxford). 2011;50(2):252–260. doi: 10.1093/rheumatology/keq298
   PubMed Web of Science ®Google Scholar
• Silva J MF, Ladomenou F, Carpenter B, et al. Allogeneic hematopoietic stem cell transplantation for severe, refractory juvenile idiopathic arthritis. Blood Adv. 2018;2(7):777–786. doi: 10.1182/bloodadvances.2017014449
   PubMed Web of Science ®Google Scholar
• Cipriani P, Carubbi F, Liakouli V, et al. Stem cells in autoimmune diseases: Implications for pathogenesis and future trends in therapy. Autoimmun Rev. 2013;12(7):709–716. doi: 10.1016/j.autrev.2012.10.004
   PubMed Web of Science ®Google Scholar
• Maumus M, Guérit D, Toupet K, et al. Mesenchymal stem cell-based therapies in regenerative medicine: applications in rheumatology. Stem Cell Res Ther. 2011;2(2):14. doi: 10.1186/scrt55
   PubMed Web of Science ®Google Scholar
• Abdelmawgoud H, Saleh A. Anti-inflammatory and antioxidant effects of mesenchymal and hematopoietic stem cells in a rheumatoid arthritis rat model. Adv Clin Exp Med. 2018;27(7):873–880. doi: 10.17219/acem/73720
   PubMed Web of Science ®Google Scholar
• Pedrosa M, Gomes J, Laranjeira P, et al. Immunomodulatory effect of human bone marrow-derived mesenchymal stromal/stem cells on peripheral blood T cells from rheumatoid arthritis patients. J Tissue Eng Regen Med. 2020;14(1):16–28. doi: 10.1002/term.2958
   PubMed Web of Science ®Google Scholar
• van Hamburg JP, Asmawidjaja PS, Davelaar N, et al. Th17 cells, but not Th1 cells, from patients with early rheumatoid arthritis are potent inducers of matrix metalloproteinases and proinflammatory cytokines upon synovial fibroblast interaction, including autocrine interleukin-17A production. Arthritis Rheum. 2011;63(1):73–83. doi: 10.1002/art.30093
   PubMed Web of Science ®Google Scholar
• Eljaafari A, Tartelin M-L, Aissaoui H, et al. Bone marrow–derived and synovium-derived mesenchymal cells promote Th17 cell expansion and activation through caspase 1 activation: Contribution to the chronicity of rheumatoid arthritis. Arthritis Rheum. 2012;64(7):2147–2157. doi: 10.1002/art.34391
   PubMedGoogle Scholar
• Sun Y, Deng W, Yao G, et al. Citrullinated fibrinogen impairs immunomodulatory function of bone marrow mesenchymal stem cells by triggering toll-like receptor. Clin Immunol. 2018;193:38–45. doi: 10.1016/j.clim.2018.01.008
   PubMed Web of Science ®Google Scholar
• Berthelot J-M, Le Goff B, Maugars Y. Bone marrow mesenchymal stem cells in rheumatoid arthritis, spondyloarthritis, and ankylosing spondylitis: problems rather than solutions? Arthritis Res Ther. 2019;21(1):239. doi: 10.1186/s13075-019-2014-8
   PubMed Web of Science ®Google Scholar
• Kastrinaki M-C, Sidiropoulos P, Roche S, et al. Functional, molecular and proteomic characterisation of bone marrow mesenchymal stem cells in rheumatoid arthritis. Ann Rheum Dis. 2008;67(6):741–749. doi: 10.1136/ard.2007.076174
   PubMed Web of Science ®Google Scholar
• Bocelli-Tyndall C, Bracci L, Spagnoli G, et al. Bone marrow mesenchymal stromal cells (BM-MSCs) from healthy donors and auto-immune disease patients reduce the proliferation of autologous- and allogeneic-stimulated lymphocytes in vitro. Rheumatology. 2007;46(3):403–408. doi: 10.1093/rheumatology/kel267
   PubMed Web of Science ®Google Scholar
• Lamas JR, Fernandez-Gutierrez B, Mucientes A, et al. RNA sequencing of mesenchymal stem cells reveals a blocking of differentiation and immunomodulatory activities under inflammatory conditions in rheumatoid arthritis patients. Arthritis Res Ther. 2019;21(1):112. doi: 10.1186/s13075-019-1894-y
   PubMedGoogle Scholar
• Kuca-Warnawin E, Kurowska W, Prochorec-Sobieszek M, et al. Rheumatoid arthritis bone marrow environment supports Th17 response. Arthritis Res Ther. 2017;19(1):274. doi: 10.1186/s13075-017-1483-x
   PubMed Web of Science ®Google Scholar
• Liu R, Li X, Zhang Z, et al. Allogeneic mesenchymal stem cells inhibited T follicular helper cell generation in rheumatoid arthritis. Sci Rep. 2015;5(1):12777. doi: 10.1038/srep12777
   PubMedGoogle Scholar
• Greish S, Abogresha N, Abdel-Hady Z, et al. Human umbilical cord mesenchymal stem cells as treatment of adjuvant rheumatoid arthritis in a rat model. World J Stem Cells. 2012;4(10):101–109. doi: 10.4252/wjsc.v4.i10.101
   PubMedGoogle Scholar
• Ma D, Xu K, Zhang G, et al. Immunomodulatory effect of human umbilical cord mesenchymal stem cells on T lymphocytes in rheumatoid arthritis. Int Immunopharmacol. 2019;74:105687. doi: 10.1016/j.intimp.2019.105687
   PubMed Web of Science ®Google Scholar
• Gu J, Gu W, Lin C, et al. Human umbilical cord mesenchymal stem cells improve the immune‑associated inflammatory and prothrombotic state in collagen type‑II‑induced arthritic rats. Mol Med Rep. 2015;12(5):7463–7470. doi: 10.3892/mmr.2015.4394
   PubMed Web of Science ®Google Scholar
• Sun Y, Kong W, Huang S, et al. Comparable therapeutic potential of umbilical cord mesenchymal stem cells in collagen-induced arthritis to TNF inhibitor or anti-CD20 treatment. Clin Exp Rheumatol. 2017;35:288–295.
   PubMed Web of Science ®Google Scholar
• Wang Q, Li X, Luo J, et al. The allogeneic umbilical cord mesenchymal stem cells regulate the function of T helper 17 cells from patients with rheumatoid arthritis in an in vitro co-culture system. BMC Musculoskelet Disord. 2012;13(1):249. doi: 10.1186/1471-2474-13-249
   PubMedGoogle Scholar
• Zeng J, Wang F, Mao M. Co‑culture of fibroblast‑like synoviocytes with umbilical cord‑mesenchymal stem cells inhibits expression of pro‑inflammatory proteins, induces apoptosis and promotes chondrogenesis. Mol Med Rep. 2016;14(4):3887–3893. doi: 10.3892/mmr.2016.5721
   PubMed Web of Science ®Google Scholar
• Kozlowska U, Krawczenko A, Futoma K, et al. Similarities and differences between mesenchymal stem/progenitor cells derived from various human tissues. World J Stem Cells. 2019;11(6):347–374. doi: 10.4252/wjsc.v11.i6.347
   PubMed Web of Science ®Google Scholar
• Ceccarelli S, Pontecorvi P, Anastasiadou E, et al. Immunomodulatory effect of adipose-derived stem cells: the cutting edge of clinical application. Front Cell Dev Biol. 2020;8:236. doi: 10.3389/fcell.2020.00236
   PubMed Web of Science ®Google Scholar
• Valencia J, Blanco B, Yáñez R, et al. Comparative analysis of the immunomodulatory capacities of human bone marrow– and adipose tissue–derived mesenchymal stromal cells from the same donor. Cytotherapy. 2016;18(10):1297–1311. doi: 10.1016/j.jcyt.2016.07.006
   PubMed Web of Science ®Google Scholar
• Baharlou R, Rashidi N, Ahmadi-Vasmehjani A, et al. Immunomodulatory effects of human adipose tissue-derived mesenchymal stem cells on T cell subsets in patients with rheumatoid arthritis. Iran J Allergy Asthma Immunol. 2019;18:114–119. doi: 10.18502/ijaai.v18i1.637
   PubMed Web of Science ®Google Scholar
• Vasilev G, Ivanova M, Ivanova-Todorova E, et al. Secretory factors produced by adipose mesenchymal stem cells downregulate Th17 and increase treg cells in peripheral blood mononuclear cells from rheumatoid arthritis patients. Rheumatol Int. 2019;39(5):819–826. doi: 10.1007/s00296-019-04296-7
   PubMed Web of Science ®Google Scholar
• Lopez-Santalla M, Mancheño-Corvo P, Menta R, et al. Human adipose-derived mesenchymal stem cells modulate experimental autoimmune arthritis by modifying early adaptive T Cell responses. Stem Cells. 2015;33(12):3493–3503. doi: 10.1002/stem.2113
   PubMed Web of Science ®Google Scholar
• Mancheño-Corvo P, Menta R, Del Río B, et al. T lymphocyte prestimulation impairs in a time-dependent manner the capacity of adipose mesenchymal stem cells to inhibit proliferation: role of interferon γ, Poly I: C, and tryptophan metabolism in restoring adipose mesenchymal stem cell inhibitory effect. Stem Cells Dev. 2015;24(18):2158–2170. doi: 10.1089/scd.2014.0508
   PubMed Web of Science ®Google Scholar
• Zhang L, Wang X-Y, Zhou P-J, et al. Use of immune modulation by human adipose-derived mesenchymal stem cells to treat experimental arthritis in mice. Am J Transl Res. 2017;9:2595–2607.
   PubMed Web of Science ®Google Scholar
• Chang Q, Li C, Lu Y, et al. Adipose-derived mesenchymal stromal cells suppress osteoclastogenesis and bone erosion in collagen-induced arthritis. Scand J Immunol. 2020;92(2):e12877. doi: 10.1111/sji.12877
   PubMed Web of Science ®Google Scholar
• Ueyama H, Okano T, Orita K, et al. Local transplantation of adipose-derived stem cells has a significant therapeutic effect in a mouse model of rheumatoid arthritis. Sci Rep. 2020;10(1):3076. doi: 10.1038/s41598-020-60041-2
   PubMed Web of Science ®Google Scholar
• Skalska U, Kuca-Warnawin E, Kornatka A, et al. Articular and subcutaneous adipose tissues of rheumatoid arthritis patients represent equal sources of immunoregulatory mesenchymal stem cells. Autoimmunity. 2017;50(8):441–450. doi: 10.1080/08916934.2017.1411481
   PubMed Web of Science ®Google Scholar
• Ibarretxe G, Crende O, Aurrekoetxea M, et al. Neural crest stem cells from dental tissues: a new hope for dental and neural regeneration. Stem Cells Int. 2012;2012:103503. doi: 10.1155/2012/103503
   PubMed Web of Science ®Google Scholar
• Anitua E, Troya M, Zalduendo M. Progress in the use of dental pulp stem cells in regenerative medicine. Cytotherapy. 2018;20(4):479–498. doi: 10.1016/j.jcyt.2017.12.011
   PubMed Web of Science ®Google Scholar
• Shi X, Mao J, Liu Y. Pulp stem cells derived from human permanent and deciduous teeth: biological characteristics and therapeutic applications. Stem Cells Transl Med. 2020;9(4):445–464. doi: 10.1002/sctm.19-0398
   PubMed Web of Science ®Google Scholar
• Croci S, Bonacini M, Dolci G, et al. Human dental pulp stem cells modulate cytokine production in vitro by peripheral blood mononuclear cells from coronavirus disease 2019 patients. Front Cell Dev Biol. 2020;8:609204. doi: 10.3389/fcell.2020.609204
   PubMed Web of Science ®Google Scholar
• Li P, Ou Q, Shi S, et al. Immunomodulatory properties of mesenchymal stem cells/dental stem cells and their therapeutic applications. Cell Mol Immunol. 2023;20(6):558–569. doi: 10.1038/s41423-023-00998-y
   PubMed Web of Science ®Google Scholar
• Zhao Y, Wang L, Jin Y, et al. Fas ligand regulates the immunomodulatory properties of dental pulp stem cells. J Dent Res. 2012;91(10):948–954. doi: 10.1177/0022034512458690
   PubMed Web of Science ®Google Scholar
• Pisciotta A, Bertani G, Bertoni L, et al. Modulation of cell death and promotion of chondrogenic differentiation by Fas/FasL in human dental pulp stem cells (hDpscs). Front Cell Dev Biol. 2020;8:279. doi: 10.3389/fcell.2020.00279
   PubMed Web of Science ®Google Scholar
• Di Tinco R, Bertani G, Pisciotta A, et al. Role of PD-L1 in licensing immunoregulatory function of dental pulp mesenchymal stem cells. Stem Cell Res Ther. 2021;12(1):598. doi: 10.1186/s13287-021-02664-4
   PubMed Web of Science ®Google Scholar
• Glennie S, Soeiro I, Dyson PJ, et al. Bone marrow mesenchymal stem cells induce division arrest anergy of activated T cells. Blood. 2005;105(7):2821–2827. doi: 10.1182/blood-2004-09-3696
   PubMed Web of Science ®Google Scholar
• Chikuma S, Terawaki S, Hayashi T, et al. PD-1-mediated suppression of IL-2 production induces CD8+ T cell anergy in vivo. J Immunol. 2009;182(11):6682–6689. doi: 10.4049/jimmunol.0900080
   PubMed Web of Science ®Google Scholar
• Duré M, Macian F. IL-2 signaling prevents T cell anergy by inhibiting the expression of anergy-inducing genes. Mol Immunol. 2009;46(5):999–1006. doi: 10.1016/j.molimm.2008.09.029
   PubMed Web of Science ®Google Scholar
• Pharoah DS, Varsani H, Tatham RW, et al. Expression of the inflammatory chemokines CCL5, CCL3 and CXCL10 in juvenile idiopathic arthritis, and demonstration of CCL5 production by an atypical subset of CD8+ T cells. Arthritis Res Ther. 2006;8(2):R50. doi: 10.1186/ar1913
   PubMed Web of Science ®Google Scholar
• Pisciotta A, Di Tinco R, Bertani G, et al. Human dental pulp stem cells (hDpscs) promote the lipofibroblast transition in the early stage of a fibro-inflammatory process. Front Cell Dev Biol. 2023;11:1196023. doi: 10.3389/fcell.2023.1196023
   PubMed Web of Science ®Google Scholar
• Pisciotta A, Riccio M, Carnevale G, et al. Stem cells isolated from human dental pulp and amniotic fluid improve skeletal muscle histopathology in mdx/SCID mice. Stem Cell Res Ther. 2015;6(1):156. doi: 10.1186/s13287-015-0141-y
   PubMedGoogle Scholar
• Zordani A, Pisciotta A, Bertoni L, et al. Regenerative potential of human dental pulp stem cells in the treatment of stress urinary incontinence: In vitro and in vivo study. Cell Proliferation. 2019;52(6):e12675. doi: 10.1111/cpr.12675
   PubMed Web of Science ®Google Scholar
• Gandia C, Armiñan A, García-Verdugo JM, et al. Human dental pulp stem cells improve left ventricular function, induce angiogenesis, and reduce infarct size in rats with acute myocardial infarction. Stem Cells. 2008;26(3):638–645. doi: 10.1634/stemcells.2007-0484
   PubMed Web of Science ®Google Scholar
• Inoue T, Sugiyama M, Hattori H, et al. Stem cells from human exfoliated deciduous tooth-derived conditioned medium enhance recovery of focal cerebral ischemia in rats. Tissue Eng Part A. 2013;19(1–2):24–29. doi: 10.1089/ten.tea.2011.0385
   PubMed Web of Science ®Google Scholar
• Botelho J, Cavacas MA, Machado V, et al. Dental stem cells: recent progresses in tissue engineering and regenerative medicine. Ann Med. 2017;49(8):644–651. doi: 10.1080/07853890.2017.1347705
   PubMed Web of Science ®Google Scholar
• Fernandes TL, Cortez de SantAnna JP, Frisene I, et al. Systematic review of human dental pulp stem cells for cartilage regeneration. Tissue Eng Part B Rev. 2020;26(1):1–12. doi: 10.1089/ten.teb.2019.0140
   PubMed Web of Science ®Google Scholar
• Matsushita Y, Ishigami M, Matsubara K, et al. Multifaceted therapeutic benefits of factors derived from stem cells from human exfoliated deciduous teeth for acute liver failure in rats. J Tissue Eng Regen Med. 2017;11(6):1888–1896. doi: 10.1002/term.2086
   PubMed Web of Science ®Google Scholar
• Mattei V, Martellucci S, Pulcini F, et al. Regenerative potential of DPSCs and revascularization: Direct, paracrine or autocrine effect? Stem Cell Rev And Rep. 2021;17(5):1635–1646. doi: 10.1007/s12015-021-10162-6
   PubMed Web of Science ®Google Scholar
• Li Y, Duan X, Chen Y, et al. Dental stem cell-derived extracellular vesicles as promising therapeutic agents in the treatment of diseases. Int J Oral Sci. 2022;14(1):2. doi: 10.1038/s41368-021-00152-2
   PubMed Web of Science ®Google Scholar
• Ishikawa J, Takahashi N, Matsumoto T, et al. Factors secreted from dental pulp stem cells show multifaceted benefits for treating experimental rheumatoid arthritis. Bone. 2016;83:210–219. doi: 10.1016/j.bone.2015.11.012
   PubMed Web of Science ®Google Scholar
• Matsubara K, Matsushita Y, Sakai K, et al. Secreted ectodomain of sialic acid-binding ig-like lectin-9 and monocyte chemoattractant protein-1 promote recovery after rat spinal cord injury by altering macrophage polarity. J Neurosci. 2015;35(6):2452–2464. doi: 10.1523/JNEUROSCI.4088-14.2015
   PubMed Web of Science ®Google Scholar
• Wakayama H, Hashimoto N, Matsushita Y, et al. Factors secreted from dental pulp stem cells show multifaceted benefits for treating acute lung injury in mice. Cytotherapy. 2015;17(8):1119–1129. doi: 10.1016/j.jcyt.2015.04.009
   PubMed Web of Science ®Google Scholar
• Janssen EM, Dy SM, Meara AS, et al. Analysis of patient preferences in lung cancer - estimating acceptable tradeoffs between treatment benefit and side effects. Patient Prefer Adherence. 2020;14:927–937. doi: 10.2147/PPA.S235430
   PubMed Web of Science ®Google Scholar
• Dong X, Kong F, Liu C, et al. Pulp stem cells with hepatocyte growth factor overexpression exhibit dual effects in rheumatoid arthritis. Stem Cell Res Ther. 2020;11(1):229. doi: 10.1186/s13287-020-01747-y
   PubMed Web of Science ®Google Scholar
• Liu L, Wong CW, Han M, et al. Meta-analysis of preclinical studies of mesenchymal stromal cells to treat rheumatoid arthritis. EBioMedicine. 2019;47:563–577. doi: 10.1016/j.ebiom.2019.08.073
   PubMed Web of Science ®Google Scholar
• Djouad F, Bouffi C, Ghannam S, et al. Mesenchymal stem cells: innovative therapeutic tools for rheumatic diseases. Nat Rev Rheumatol. 2009;5(7):392–399.**. doi: 10.1038/nrrheum.2009.104
   PubMed Web of Science ®Google Scholar
• Sullivan KM, Sarantopoulos S. Allogeneic HSCT for autoimmune disease: a shared decision. Nat Rev Rheumatol. 2019;15(12):701–702. doi: 10.1038/s41584-019-0306-7
   PubMed Web of Science ®Google Scholar
• Jaime-Pérez JC, González-Treviño M, Meléndez-Flores JD, et al. Autologous ATG-free hematopoietic stem cell transplantation for refractory autoimmune rheumatic diseases: a Latin American cohort. Clin Rheumatol. 2022;41(3):869–876. doi: 10.1007/s10067-021-05931-0
   PubMed Web of Science ®Google Scholar
• Mehta K, Jaiswal P, Briggs F, et al. In-patient outcomes of hematopoietic stem Cell transplantation in patients with immune mediated inflammatory diseases: a nationwide study. Sci Rep. 2018;8(1):6825. doi: 10.1038/s41598-018-24060-4
   PubMedGoogle Scholar
• Snowden JA, Kapoor S, Wilson AG. Stem cell transplantation in rheumatoid arthritis. Autoimmunity. 2008;41(8):625–631. doi: 10.1080/08916930802198550
   PubMed Web of Science ®Google Scholar
• Muthu S, Jeyaraman M, Ranjan R, et al. Remission is not maintained over 2 years with hematopoietic stem cell transplantation for rheumatoid arthritis: A systematic review with meta-analysis. World J Biol Chem. 2021;12(6):114–130. doi: 10.4331/wjbc.v12.i6.114
   PubMedGoogle Scholar
• Swart JF, Delemarre EM, van Wijk F, et al. Haematopoietic stem cell transplantation for autoimmune diseases. Nat Rev Rheumatol. 2017;13(4):244–256. doi: 10.1038/nrrheum.2017.7
   PubMed Web of Science ®Google Scholar
• Snowden JA, Sharrack B, Akil M, et al. Autologous haematopoietic stem cell transplantation (aHSCT) for severe resistant autoimmune and inflammatory diseases – a guide for the generalist. Clin Med. 2018;18(4):329–334. doi: 10.7861/clinmedicine.18-4-329
   PubMed Web of Science ®Google Scholar
• Alavi M, Tavakkol-Afshari J, Shariati-Sarabi Z, et al. Intravenous injection of autologous bone marrow-derived mesenchymal stem cells on the gene expression and plasma level of CCL5 in refractory rheumatoid arthritis. J Res Med Sci. 2020;25(1):111. doi: 10.4103/jrms.JRMS_308_20
   PubMedGoogle Scholar
• Ghoryani M, Shariati-Sarabi Z, Tavakkol-Afshari J, et al. Amelioration of clinical symptoms of patients with refractory rheumatoid arthritis following treatment with autologous bone marrow-derived mesenchymal stem cells: A successful clinical trial in Iran. Biomed Pharmacother. 2019;109:1834–1840. doi: 10.1016/j.biopha.2018.11.056
   PubMed Web of Science ®Google Scholar
• Wang L, Wang L, Cong X, et al. Human umbilical cord mesenchymal stem cell therapy for patients with active rheumatoid arthritis: safety and efficacy. Stem Cells Dev. 2013;22(24):3192–3202. doi: 10.1089/scd.2013.0023
   PubMed Web of Science ®Google Scholar
• Shadmanfar S, Labibzadeh N, Emadedin M, et al. Intra-articular knee implantation of autologous bone marrow–derived mesenchymal stromal cells in rheumatoid arthritis patients with knee involvement: Results of a randomized, triple-blind, placebo-controlled phase 1/2 clinical trial. Cytotherapy. 2018;20(4):499–506. doi: 10.1016/j.jcyt.2017.12.009
   PubMed Web of Science ®Google Scholar
• Vij R, Stebbings KA, Kim H, et al. Safety and efficacy of autologous, adipose-derived mesenchymal stem cells in patients with rheumatoid arthritis: a phase I/IIa, open-label, non-randomized pilot trial. Stem Cell Res Ther. 2022;13(1):88. doi: 10.1186/s13287-022-02763-w
   PubMed Web of Science ®Google Scholar
• Álvaro-Gracia JM, Jover JA, García-Vicuña R, et al. Intravenous administration of expanded allogeneic adipose-derived mesenchymal stem cells in refractory rheumatoid arthritis (Cx611): results of a multicentre, dose escalation, randomised, single-blind, placebo-controlled phase Ib/IIa clinical trial. Ann Rheum Dis. 2017;76(1):196–202. doi: 10.1136/annrheumdis-2015-208918
   PubMed Web of Science ®Google Scholar
• Jo CH, Lee YG, Shin WH, et al. Intra-articular injection of mesenchymal stem cells for the treatment of osteoarthritis of the knee: a proof-of-concept clinical trial. Stem Cells. 2014;32(5):1254–1266. doi: 10.1002/stem.1634
   PubMed Web of Science ®Google Scholar
• Lv X, Wang L, Zou X, et al. Umbilical cord mesenchymal stem cell therapy for regenerative treatment of rheumatoid arthritis: opportunities and challenges. Drug Des Devel Ther. 2021;15:3927–3936. doi: 10.2147/DDDT.S323107
   PubMed Web of Science ®Google Scholar
• Chen Y, Zhang Q, Peng W, et al. Efficacy and safety of mesenchymal stem cells for the treatment of patients infected with COVID-19: a systematic review and meta-analysis protocol. BMJ Open. 2020;10(12):e042085. doi: 10.1136/bmjopen-2020-042085
   PubMed Web of Science ®Google Scholar
• Jiang P, Mao L, Qiao L, et al. Efficacy and safety of mesenchymal stem cell injections for patients with osteoarthritis: a meta-analysis and review of RCTs. Arch Orthop Trauma Surg. 2021;141(7):1241–1251. doi: 10.1007/s00402-020-03703-0
   PubMed Web of Science ®Google Scholar
• Li T, Luo C, Zhang J, et al. Efficacy and safety of mesenchymal stem cells co-infusion in allogeneic hematopoietic stem cell transplantation: a systematic review and meta-analysis. Stem Cell Res Ther. 2021;12(1):246. doi: 10.1186/s13287-021-02304-x
   PubMed Web of Science ®Google Scholar
• Cui J, Jin L, Ding M, et al. Efficacy and safety of mesenchymal stem cells in the treatment of systemic sclerosis: a systematic review and meta-analysis. Stem Cell Res Ther. 2022;13(1):118. doi: 10.1186/s13287-022-02786-3
   PubMed Web of Science ®Google Scholar
• Wright A, Arthaud-Day ML, Weiss ML. Therapeutic use of mesenchymal stromal cells: the need for inclusive characterization guidelines to accommodate all tissue sources and species. Front Cell Dev Biol [Internet]. 2021;9 [cited 2023 Apr 5]. doi: 10.3389/fcell.2021.632717
   Web of Science ®Google Scholar
• ISSCR Guidelines [Internet]. [cited 2022 Apr 20]. Available from: https://www.isscr.org/policy/guidelines-for-stem-cell-research-and-clinical-translation.
   Google Scholar
• Wang Y, Huang J, Gong L, et al. The plasticity of mesenchymal stem cells in regulating surface HLA-I. iScience. 2019;15:66–78. doi: 10.1016/j.isci.2019.04.011
   PubMed Web of Science ®Google Scholar
• Petrus-Reurer S, Romano M, Howlett S, et al. Immunological considerations and challenges for regenerative cellular therapies. Commun Biol. 2021;4(1):1–16. doi: 10.1038/s42003-021-02237-4
   PubMed Web of Science ®Google Scholar
• Jossen V, van den Bos C, Eibl R, et al. Manufacturing human mesenchymal stem cells at clinical scale: process and regulatory challenges. Appl Microbiol Biotechnol. 2018;102(9):3981–3994. doi: 10.1007/s00253-018-8912-x
   PubMed Web of Science ®Google Scholar
• Czapla J, Matuszczak S, Kulik K, et al. The effect of culture media on large-scale expansion and characteristic of adipose tissue-derived mesenchymal stromal cells. Stem Cell Res Ther. 2019;10(1):235. doi: 10.1186/s13287-019-1331-9
   PubMed Web of Science ®Google Scholar
• Harrell CR, Volarevic A, Djonov VG, et al. Mesenchymal stem Cell: a friend or foe in Anti-tumor immunity. Int J Mol Sci. 2021;22(22):12429. doi: 10.3390/ijms222212429
   PubMed Web of Science ®Google Scholar
• Liang W, Chen X, Zhang S, et al. Mesenchymal stem cells as a double-edged sword in tumor growth: focusing on MSC-derived cytokines. Cell Mol Biol Lett. 2021;26(1):3. doi: 10.1186/s11658-020-00246-5
   PubMed Web of Science ®Google Scholar
• Guiotto M, Raffoul W, Hart AM, et al. Human platelet lysate to substitute fetal bovine serum in hMSC expansion for translational applications: a systematic review. J Transl Med. 2020;18(1):351. doi: 10.1186/s12967-020-02489-4
   PubMed Web of Science ®Google Scholar
• Palombella S, Perucca Orfei C, Castellini G, et al. Systematic review and meta-analysis on the use of human platelet lysate for mesenchymal stem cell cultures: comparison with fetal bovine serum and considerations on the production protocol. Stem Cell Res Ther. 2022;13(1):142. doi: 10.1186/s13287-022-02815-1
   PubMed Web of Science ®Google Scholar
• Oikonomopoulos A, van Deen WK, Manansala A-R, et al. Optimization of human mesenchymal stem cell manufacturing: the effects of animal/xeno-free media. Sci Rep. 2015;5(1):16570. doi: 10.1038/srep16570
   PubMedGoogle Scholar
• Bui HTH, Nguyen LT, Than UTT. Influences of xeno-free media on mesenchymal stem Cell expansion for clinical application. Tissue Eng Regen Med. 2021;18(1):15–23. doi: 10.1007/s13770-020-00306-z
   PubMed Web of Science ®Google Scholar
• Han L, Ma C, Peng H, et al. Define mesenchymal stem cell from its fate: biodisposition of human mesenchymal stem cells in normal and concanavalin A–induced liver injury mice. J Pharmacol Exp Ther. 2021;379(2):125–133. doi: 10.1124/jpet.121.000607
   PubMed Web of Science ®Google Scholar
• Masterson CH, Tabuchi A, Hogan G, et al. Intra-vital imaging of mesenchymal stromal cell kinetics in the pulmonary vasculature during infection. Sci Rep. 2021;11(1):5265. doi: 10.1038/s41598-021-83894-7
   PubMed Web of Science ®Google Scholar
• Kallmeyer K, André-Lévigne D, Baquié M, et al. Fate of systemically and locally administered adipose-derived mesenchymal stromal cells and their effect on wound healing. Stem Cells Transl Med. 2020;9(1):131–144. doi: 10.1002/sctm.19-0091
   PubMed Web of Science ®Google Scholar
• Karamini A, Bakopoulou A, Andreadis D, et al. Therapeutic potential of mesenchymal stromal stem cells in rheumatoid arthritis: a systematic review of in vivo studies. Stem Cell Rev And Rep. 2020;16(2):276–287. doi: 10.1007/s12015-020-09954-z
   PubMed Web of Science ®Google Scholar
• Moll G, Ankrum JA, Kamhieh-Milz J, et al. Intravascular mesenchymal stromal/stem cell therapy product diversification: time for new clinical guidelines. Trends Mol Med. 2019;25(2):149–163. doi: 10.1016/j.molmed.2018.12.006
   PubMed Web of Science ®Google Scholar
• Bagno LL, Salerno AG, Balkan W, et al. Mechanism of action of mesenchymal stem cells (MSCs): impact of delivery method. Expert Opin Biol Ther. 2022;22(4):449–463. doi: 10.1080/14712598.2022.2016695
   PubMed Web of Science ®Google Scholar
• Satué M, Schüler C, Ginner N, et al. Intra-articularly injected mesenchymal stem cells promote cartilage regeneration, but do not permanently engraft in distant organs. Sci Rep. 2019;9(1):10153. doi: 10.1038/s41598-019-46554-5
   PubMedGoogle Scholar
• To K, Khan W. Mesenchymal stem cell transplantation in rheumatoid arthritis. In: Pham P editor. Stem cell transplantation for autoimmune diseases and inflammation [Internet]. Cham: Springer International Publishing; 2019 [cited 2022 Apr 20]. p. 63–74. doi: 10.1007/978-3-030-23421-8_4
   Google Scholar
• Rad F, Ghorbani M, Mohammadi Roushandeh A, et al. Mesenchymal stem cell-based therapy for autoimmune diseases: emerging roles of extracellular vesicles. Mol Biol Rep. 2019;46(1):1533–1549. doi: 10.1007/s11033-019-04588-y
   PubMed Web of Science ®Google Scholar
• Alghamdi M, Alamry SA, Bahlas SM, et al. Circulating extracellular vesicles and rheumatoid arthritis: a proteomic analysis. Cell Mol Life Sci. 2021;79(1):25. doi: 10.1007/s00018-021-04020-4
   PubMed Web of Science ®Google Scholar
• Huldani H, Abdalkareem Jasim S, Olegovich Bokov D, et al. Application of extracellular vesicles derived from mesenchymal stem cells as potential therapeutic tools in autoimmune and rheumatic diseases. Int Immunopharmacol. 2022;106:108634. doi: 10.1016/j.intimp.2022.108634
   PubMed Web of Science ®Google Scholar
• Wang M, Yuan Q, Xie L. Mesenchymal stem cell-based immunomodulation: properties and clinical application. Stem Cells Int. 2018;2018:3057624. doi: 10.1155/2018/3057624
   PubMed Web of Science ®Google Scholar
• Shi Y, Wang Y, Li Q, et al. Immunoregulatory mechanisms of mesenchymal stem and stromal cells in inflammatory diseases. Nat Rev Nephrol. 2018;14(8):493–507. doi: 10.1038/s41581-018-0023-5
   PubMed Web of Science ®Google Scholar
• Turner L. ISSCR’s Guidelines for stem cell research and clinical translation: supporting development of safe and efficacious stem cell-based interventions. Stem Cell Rep. 2021;16(6):1394–1397. doi: 10.1016/j.stemcr.2021.05.011
   PubMed Web of Science ®Google Scholar
• Guleria I, de Los Angeles Muñiz M, Wilgo M, et al. How do I: Evaluate the safety and legitimacy of unproven cellular therapies? Transfusion. 2022;62(3):518–532. doi: 10.1111/trf.16814
   PubMed Web of Science ®Google Scholar
• Bakopoulou A, Apatzidou D, Aggelidou E, et al. Isolation and prolonged expansion of oral mesenchymal stem cells under clinical-grade, GMP-compliant conditions differentially affects “stemness” properties. Stem Cell Res Ther. 2017;8(1):247. doi: 10.1186/s13287-017-0705-0
   PubMed Web of Science ®Google Scholar
• Lechanteur C, Briquet A, Bettonville V, et al. MSC manufacturing for academic clinical trials: from a clinical-grade to a full GMP-compliant process. Cells. 2021;10(6):1320. doi: 10.3390/cells10061320
   PubMed Web of Science ®Google Scholar
• Sanz-Nogués C, O’Brien T. Current good manufacturing practice considerations for mesenchymal stromal cells as therapeutic agents. Biomater Biosyst. 2021;2:100018. doi: 10.1016/j.bbiosy.2021.100018
   PubMedGoogle Scholar
• Tyndall A, Walker UA, Cope A, et al. Immunomodulatory properties of mesenchymal stem cells: a review based on an interdisciplinary meeting held at the Kennedy Institute of Rheumatology Division, London, UK, 31 October 2005. Arthritis Res Ther. 2007;9:301. doi: 10.1186/ar2103
   PubMed Web of Science ®Google Scholar
• Jiang W, Xu J. Immune modulation by mesenchymal stem cells. Cell Proliferation. 2020;53(1):e12712. doi: 10.1111/cpr.12712
   PubMed Web of Science ®Google Scholar
• Askenasy N. Enhanced killing activity of regulatory T cells ameliorates inflammation and autoimmunity. Autoimmun Rev. 2013;12(10):972–975. doi: 10.1016/j.autrev.2013.04.005
   PubMed Web of Science ®Google Scholar
• Negi N, Griffin MD. Effects of mesenchymal stromal cells on regulatory T cells: Current understanding and clinical relevance. Stem Cells. 2020;38(5):596–605. doi: 10.1002/stem.3151
   PubMed Web of Science ®Google Scholar
• François M, Romieu-Mourez R, Li M, et al. Human MSC suppression correlates with cytokine induction of indoleamine 2,3-dioxygenase and bystander M2 macrophage differentiation. Mol Ther. 2012;20(1):187–195. doi: 10.1038/mt.2011.189
   PubMed Web of Science ®Google Scholar
• Luz-Crawford P, Jorgensen C, Djouad F. Mesenchymal stem cells direct the immunological fate of macrophages. In: Kloc M editor. Macrophages: origin, functions and biointervention [Internet]. Cham: Springer International Publishing; 2017 [cited 2023 Apr 11]. p. 61–72. doi: 10.1007/978-3-319-54090-0_4
   Google Scholar
• Suzdaltseva Y, Goryunov K, Silina E, et al. Equilibrium among inflammatory factors determines human MSC-Mediated immunosuppressive effect. Cells. 2022;11(7):1210. doi: 10.3390/cells11071210
   PubMed Web of Science ®Google Scholar
• Waterman RS, Tomchuck SL, Henkle SL, et al. A new mesenchymal stem cell (MSC) paradigm: polarization into a pro-inflammatory MSC1 or an immunosuppressive MSC2 phenotype. PLoS One. 2010;5(4):e10088. doi: 10.1371/journal.pone.0010088
   PubMed Web of Science ®Google Scholar
• Dehnavi S, Sadeghi M, Tavakol Afshari J, et al. Interactions of mesenchymal stromal/stem cells and immune cells following MSC-based therapeutic approaches in rheumatoid arthritis. Cell Immunol. 2023;393–394:104771.
   PubMed Web of Science ®Google Scholar
• De Bari C. Are mesenchymal stem cells in rheumatoid arthritis the good or bad guys? Arthritis Res Ther. 2015;17(1):113. doi: 10.1186/s13075-015-0634-1
   PubMedGoogle Scholar
• Murray IR, Chahla J, Safran MR, et al. International expert consensus on a cell therapy communication tool: DOSES. JBJS. 2019;101(10):904. doi: 10.2106/JBJS.18.00915
   PubMed Web of Science ®Google Scholar
• Peltzer J, Aletti M, Frescaline N, et al. Mesenchymal stromal cells based therapy in systemic sclerosis: rational and challenges. Front Immunol [Internet]. 2018 [cited 2023 Nov 8];9. doi: 10.3389/fimmu.2018.02013
   PubMed Web of Science ®Google Scholar
• Műzes G, Sipos F. Issues and opportunities of stem cell therapy in autoimmune diseases. World J Stem Cells. 2019;11(4):212–221. doi: 10.4252/wjsc.v11.i4.212
   PubMed Web of Science ®Google Scholar